The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 28, 2025
Filed:
Oct. 28, 2019
Applicant:
Genmab A/s, Copenhagen V, DK;
Inventors:
Reshma Abdulla Rangwala, Philadelphia, PA (US);
Sandra Verploegen, Nieuwegein, NL;
Esther C. W. Breij, Driebergen, NL;
Oyewale O. Abidoye, Bellevue, WA (US);
Leonardo Viana Nicacio, Redmond, WA (US);
Assignee:
Genmab A/S, Valby, DK;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); C07K 16/36 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6869 (2017.08); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/36 (2013.01); A61K 2039/507 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01);
Abstract
The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.